Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

7 treatments under study, led by Vxag11nn Low Dose Oral Vaccine Tablet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 3 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

3Total
Phase 1 (3)

Trial Status

Completed2
Recruiting1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 2 completed trials

Clinical Trials (3)

Showing 3 of 3 trials
NCT07818629Phase 1Recruiting

A Study to Evaluate INT101 in Healthy Adults for the Prevention of Norovirus Gastroenteritis

NCT02868073Phase 1CompletedPrimary

Phase 1 Placebo-controlled, Randomized Trial of an Adenoviral-vector Based Norovirus Vaccine

NCT03125473Phase 1CompletedPrimary

Dose-Optimization Trial of VXA-G1.1-NN in Healthy Volunteers

Showing all 3 trials

Research Network

Common Treatments

  • Vxag11nn Low Dose Oral Vaccine Tablet1
  • Int101 High Dose1
  • Int101 Low Dose1
  • Int101 Placebo 05 Ml1
  • Vxag11nn Oral Vaccine1

Active Sponsors

  • Vaxart2
  • InThera Inc. Korea1

Top Investigators

Related Conditions

  • Norovirus Infections1

Activity Timeline